Evidence map›Paper›PMID 42188776›Full record

ArticleVaccines2026

Safety and Field Performance of a Monovalent Vaccine Against Variant

Anette Furevik, Hege Jørstad Sekkenes, Bjørn Ellingsen, Ane Sandtrø, Svein Alexandersen, Øyvind Tønnessen, Binoy Rajan, Lars Gaute Jørgensen, Ingrid Margrethe Hagerup, Lisa Marie Leknes and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anette FurevikPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Hege Jørstad SekkenesPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Bjørn EllingsenPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Ane SandtrøPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Svein AlexandersenPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Øyvind TønnessenPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Binoy RajanPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Lars Gaute JørgensenPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Ingrid Margrethe HagerupPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Lisa Marie LeknesPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Siv Haugen TunheimPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Ida Steine OmaPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Christél TeiePHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.
Jostein Mulder PettersenSalmalytics AS, Ullevålsveien 68, Bygning 23, 0454 Oslo, Norway.ORCID 0009-0009-6031-3950
Monica Gausdal-TingbøPHARMAQ AS, Skøyen, P.O. Box 267, 0213 Oslo, Norway.

Funding

The Research Council of Norway 318932
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aquacultureAtlantic salmonfield trialfish vaccineMoritella viscosawinter ulcer disease

Identifiers

PMID42188776
PMCPMC13211632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.